S1E19 / A Return to Sports, a Return to “Normal” Life? / Rohan Nadkarni, Grant Wahl, and Peter King
Play • 25 min

Transcript

"I can't stress this enough. Rudy Gobert testing positive was the best thing that happened for the NBA. It arguably, in many ways, is the best thing that happened for this country. I don't think people were taking this seriously, Celine, until they found out an entity like the NBA could suspend its season because of the coronavirus.” -Rohan Nadkarni

In this episode, our co-hosts Dr. Celine Gounder and Ron Klain speak to Rohan Nadkarni, Grant Wahl, and Peter King and look at the pandemic through the lens of basketball, soccer, and football to see how COVID is changing the way sports are played. They discuss what these games might look like for fans and players when they resume, how COVID is affecting the business of sports, and what the consequences are of trying to play sports in the middle of the pandemic. Grant Wahl is America's leading soccer journalist. He spent 24 years at Sports Illustrated, covering college basketball and soccer, and is the author of the New York Times bestseller, “ The Beckham Experiment,” as well as “Masters of Modern Soccer.” Rohan Nadkarni covers basketball for Sports Illustrated. Peter King covers football for NBC Sports, is the author of five books, and has been named National Sportswriter of the Year three times.

This podcast was created by Just Human Productions. We're powered and distributed by Simplecast. We're supported, in part, by listeners like you.

#SARSCoV2 #COVID19 #COVID #coronavirus

Mayo Clinic Talks
Mayo Clinic Talks
Mayo Clinic
COVID-19 Miniseries Episode 66: Monoclonal Antibody Treatment for COVID-19
Guest: Ravindra Ganesh, M.B.B.S., M.D. and Raymund R. Razonable, M.D. Host: Amit K. Ghosh, M.D. (@AmitGhosh006) In this episode, Ravindra Ganesh, M.B.B.S., M.D. and Raymund R. Razonable, M.D. join Amit K. Ghosh, M.D. to review the use of monoclonal antibody as a new antiviral agent in the treatment of COVID-19 infection. Who is most likely to benefit from monoclonal antibody infusions? Drs. Ganesh and Razonable, discuss recent studies on monoclonal antibody infusions in patients with mild to moderate COVID-19 infections. Also discussed are the logistical challenges faced and the innovative solutions that were implemented while administering this therapy, particularly navigating the acceptance of treatment, its real and perceived side effects, and lack of awareness due to inequity and poverty. Research on the development of subcutaneous or intramuscular administration for prophylaxis against COVID-19 in patients at high risk for complications or at high risk for being exposed to SARS-CoV-2 is also discussed in this episode. Additional resources: * AskMayoExpert COVID-19 Navigator: https://askmayoexpert.mayoclinic.org/navigator/COVID-19 * Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384:238-251. * Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384:229-237. * Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.JAMA. Published online January 21, 2021. doi:10.1001/jama.2021.0202 * An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19. JAMA. Published online December 11, 2020. doi:10.1001/jama.2020.24415 * Monoclonal Antibodies: Update on this COVID-19 Experimental Therapy https://discoverysedge.mayo.edu/2021/02/17/monoclonal-antibodies-update-on-this-covid-19-experimental-therapy/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
26 min
More episodes
Search
Clear search
Close search
Google apps
Main menu